SCHEMBL13676002

SCHEMBL13676002

COC(=O)C1CNc2cc(NC(=O)CCc3ccc(C(C)(C)C)cc3)ccc2O1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 3/20 0.57
CYSLTR1 Q9Y271 2/20 0.46
TSHR P16473 1/20 0.46
ROCK2 O75116 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MCHR1 Q99705 2/20 0.40
NR1H4 Q96RI1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13676035 0.92 TRPV1 (0.55) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676016 0.91 TRPV1 (0.59) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676032 0.89 TRPV1 (0.57) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676022 0.88 TRPV1 (0.56) TRPV1CYSLTR1TSHRALDH1A1HSD17B10
SCHEMBL13712656 0.87 TRPV1 (0.61) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676143 0.86 TRPV1 (0.56) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676024 0.85 TRPV1 (0.59) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676276 0.84 TRPV1 (0.58) TRPV1CYSLTR1TSHRROCK2ALDH1A1
SCHEMBL13676042 0.83 TRPV1 (0.56) TRPV1TSHRALDH1A1NPC1RAB9A
SCHEMBL13675728 0.80 TRPV1 (0.65) TRPV1TSHRNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885CYSLTR1 136/4885TSHR 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.